top of page
A Closer Look

RESEARCH GRANT AWARDS

AWARDS LIST.

Totals by Year

2023 - $891,364

2022 - $1,199,966

2021 - $749,812

2020 - $630,000

2019 - $690,000

2018 - $750,000

2017 - $747,772

2016 - $720,000

2015 - $840,000

2014 - $810,000

2013 - $808,500

2012 - $720,000

2011 - $599,780

2010 - $438,000

2009 - $435,000

2008 - $619,993

2007 - $232,600

2006 - $384,551

Amounts flagged (*) below are 50% funded by Cancer League of Colorado and 50% matched by MDC/RICHMOND AMERICAN HOMES FOUNDATION.

Ke Jun Han PhD with Changwei Liu

Regulating EGFR protein levels by a deubiquitinaying enzyme in cancer cells

30,000

2013

Nicholas Foreman MD

Development of Antibody as immunotherapy for pediatric brain tumors

30,000

2013

John Tentler PhD

Cancer Research Fellowship Program

 $30,000

2013

Chu An Wang, Dept. of Pharm.

Targeting Vascular Endothelial Growth Factor C in the cancer stem like population sensitizes breast Ccncer cells to oxidize stress and onhibits tumor progression

30,000

2013

Steven Anderson and Mary Reyland

Protein Kinase C Delta and breast cancer therapeutics

30,000

2013

Quinghong Zang PhD

Targeting Melanoma Photocinogeneses by blocking C+BP1

30,000

2013

Robert Keith MD with Gregory Hickey, Fellow

Pre-Clinical Investigation of Treprostinil as a Cemopreventive Agent for non-small cell lung cancer

30,000

2013

York Miller MD and Mark Geraci MD

Bronchial Somatic Chromosomal Alterations in lung cancer risk

30,000

2013

Elizabeth Kessler MD, Fellow

Effects of Androgen Deprivation Therapy on geriatric health and physical function in men over 70 years of age with prostate cancer

30,000

2013

Joy Hesselberth PhD

Defining the role of SF 381 mutations in Leukemia

30,000

2013

Thomas Rodger, postdoctoral fellow

Targeting the Kynurenine Pathway to inhibit breast cancer metastases

30,000

2013

Pepper Schedin, PhD

Investigating the role of lymphangiogenesis and lymphovascular invasion in metastasis of postpartum breast cancer

30,000

2012

David Astling, PhD

Development of an Improved Classifier for Predicting Multiple Drug Classes and Molecular Targets for Tumor Subtypes

30,000

2012

Peter Kabos, MD

Role of alternative polyadenylation in estrogen receptor positive breast cancer

30,000

2012

Uday Kompella, PhD

Novel Lung Cancer Therapeutics

30,000

2012

Ann Thor, MD/ Reema Wahdan-Alaswad, PhD

Metformin Inhibits Metastasis in Triple Negative Breast Cancer

30,000

2012

Jill Slansky, PhD Tullio Bruno, PhD

Characterizing the Function and Location of B Cells in Lung Cancer

30,000

2012

Shi-Long Lu, PhD

Tumor cell Dissemination and Metastasis Initiation in Head and Neck Cancer

30,000

2012

Michelle Guney, PhD

The Role of Eya in breast cancer metastic progression

30,000

2012

Bolin Liu, MD

Epignetic induction of erbB2/erbB3-targeting miRNAs in breast cancer

30,000

2012

Eduardo Pajon, MD

Colorado Cancer Research Program

30,000

2012

Catherine Musselman, PhD

The Role of PHF1 in the repressive activity of PRC2

30,000

2012

Michael J. Morgan, PhD

Autophagy Dependence and Chloroquine Sensitivity in Metastatic Cancer

30,000

2012

Rui Zhao, PhD Quinghong Zhang, PhD

Inhibiting the transcriptional co-repressor CtBP for cancer therapy using cell penetrating peptide

60,000

2012

Jingshi Shen, PhD

Dissection of the perforin pathway in cancer immunotherapy

30,000

2012

Colin Moore, MD

Evaluating the Role of miR 193b in Ewing Sarcoma growth Suppression

30,000

2012

Caroline Kulesza, PhD

Virus Manipulation of a Cellular Chromatin Modifying Complex

30,000

2012

Jordan Jacobelli, PhD

Regulation of lymphoma dissemination by the actin-myosin cytoskeleton

30,000

2012

Amanda Guth, DVM, PhD

Monocyte Blockade with CCR2 Antagonists for Inhibition of tumor metastases

30,000

2012

Robert Doebele, MD, PhD Kurtis D. Davies, PhD

Acquired Resistance to ROS1 inhibition in Non-Small Cell Lung Cancer: Identification of Cellular Mechanisms and Exploration of Alternative Treatment Strategies

30,000

2012

Stephen Malkoski, MD Scott Cramer, PhD

Defining the role of TAK1 in non-small cell lung cancer

60,000

2012

Marileila Varella Garcia, PhD

2012 Cancer Research Summer Fellowship Program

30,000

2012

Antonio Jimeno, MD, PhD Gregory Gan, MD, PhD

Resistance of Human Head and Neck Squamous Cell Carcinoma to Concurrent EGFR and Radiotherapy Mediated Through the Hedgehog Pathway

30,000

2012

Dawn Duval, Ph.D.

Osteosarcoma: Biomarkers of Metastasis and Resistance to Therapy

30,000

2011

James Lambert, Ph.D.

Genome-wide RA interference screen for mediators of cell death induced by a novel vitamin D analog in triple negative breast cancer

30,000

2011

Kim Jihye, Ph.D.

PathCMap Development of pathway signature system for identifying partners of synethetic lethal genes

30,000

2011

Sunshine Axlund, Ph.D.

Tumor initiating and Drug Resistant Properties of a minor Population of Stem-Like Cells in Explant Models of Estrogen Receptor Positive Human Breast Tumors

30,000

2011

Raul Torres, Ph.D.

LPA Regulation of T Cell Tumor Immunity

30,000

2011

Marileila Varella Garcia, Ph.D.

Cancer Research Summer Fellowship Program

30,000

2011

Christopher Porter, M.D. and Jean Mulcahy, M.D.

High Throughput Functional Genetic Screening to Define the Role of Autophagy in Pediatric Brain Tumors

60,000

2011

Henry Thompson, Ph.D. and Barbara Wallner, Ph.D.

Competency Development to Reduce Obesity and Promote Long Term Survival Following treatment for Breast Cancer

59,780

2011

Steve Anderson, Ph.D.

Does cell surface transporter expression determine the response of breast cancer

30,000

2011

Andrew Bradford, Ph.D.

PKCδ as a biomarker and regulator of response to chemotherapy in endometrial cancer

30,000

2011

Rytis Prekeris, Ph.D., and Pepper Schedin, Ph.D.

The regulation of MMP Secretion During the Invasion of Breast Cancer Cells

60,000

2011

Dylan Taatjes, Ph.D.

Identification of transcriptional cofactors that trigger alternations in breast cancer pathology and therapeutic response

30,000

2011

Lindsay Micel, M.D.

Identifying mechanisms of resistance to the novel NAE inhibitor, MLN4924, in melanoma

30,000

2011

Quinghong Zhang, Ph.D.

The Role of CtBP1 in SCC

30,000

2011

Dawn Cochrane, Ph.D.

Restoring miR-200c to aggressive ovarian cancers to attack anoikis resistance

30,000

2011

Pajon, Eduardo, Jr., M.D.

Colorado Cancer Research Clinical Trials Program

30,000

2011

Renee Paulson, Ph.D.

Elucidating the cellular response to hypoxia via functional genomics

30,000

2011

bottom of page